<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Soluble CD163 (sCD163) was recently identified as a strong risk marker for developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesised that sCD163 independently associates with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: This cross-sectional study includes 234 participants: 96 with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 34 with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (IGT) and 104 with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance (NGT), matched for sex and BMI </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi>-lowering medication was paused for 1 week before plasma samples were obtained for determination of sCD163 and other inflammatory and metabolic variables </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> was estimated by homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (HOMA-IR) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Concentrations of sCD163 were 1.95 mg/l (0.63-6.97) in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 1.64 mg/l (0.58-4.19) in those with IGT, and 1.48 mg/l (0.48-4.11) (median [range]) in those with NGT (p &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>In univariate analyses, sCD163 correlated significantly with HOMA-IR (R = 0.44), insulin (R = 0.41), <z:chebi fb="105" ids="17234">glucose</z:chebi> (R = 0.30), triacylglycerol (R = 0.29) and <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (R = -0.34) (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but <z:chebi fb="105" ids="17234">glucose</z:chebi> remained significant when adjusting for age, sex, BMI and glycaemic group </plain></SENT>
<SENT sid="8" pm="."><plain>In univariate regression analyses, HOMA-IR was associated with sCD163, C-reactive protein (CRP), TNF-α and IL-6 (<z:hpo ids='HP_0000001'>all</z:hpo> p ≤ 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>An increase of 50% in sCD163 resulted in an estimated increase in HOMA-IR of 36% (95% CI 26, 48; p &lt; 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>In multiple linear regression analyses, sCD163 (p = 0.001) and CRP (p = 0.01) remained independent predictors of HOMA-IR, whereas TNF-α and IL-6 did not </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS/INTERPRETATION: Macrophage-specific sCD163 was strongly associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> independently of TNF-α and other predictors </plain></SENT>
<SENT sid="12" pm="."><plain>Moreover, sCD163 was associated with well-known variables of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>